{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:39:27Z","timestamp":1785800367881,"version":"3.56.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Anusandhan National Research Foundation (ANRF) [earlier Science and Engineering Research Board (SERB)], Department of Science and Technology, Govt. of India","award":["EEQ\/2023\/000014"],"award-info":[{"award-number":["EEQ\/2023\/000014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00210-025-04870-w","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T11:07:52Z","timestamp":1764846472000},"page":"7149-7166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Risedronate attenuates renal fibrosis by targeting prenylation-dependent RhoA\/ROCK1 and ERK\/NF-\u03baB signaling"],"prefix":"10.1007","volume":"399","author":[{"given":"Rohan","family":"Bhadange","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4627-5504","authenticated-orcid":false,"given":"Anil Bhanudas","family":"Gaikwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"issue":"12","key":"4870_CR1","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s00210-018-1544-y","volume":"391","author":"NA Abbas","year":"2018","unstructured":"Abbas NA, El. Salem A, Awad MM (2018) Empagliflozin, SGLT2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expression. Naunyn Schmiedebergs Arch Pharmacol 391(12):1347\u20131360","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"11","key":"4870_CR2","doi-asserted-by":"publisher","first-page":"8961","DOI":"10.1007\/s00210-024-03146-z","volume":"397","author":"MA AbouTaha","year":"2024","unstructured":"AbouTaha MA, Ali FE, Saleh IG, Akool E-S (2024) Sorafenib and edaravone protect against renal fibrosis induced by unilateral ureteral obstruction via inhibition of oxidative stress, inflammation, and RIPK-3\/MLKL pathway. Naunyn Schmiedebergs Arch Pharmacol 397(11):8961\u20138977","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"4870_CR3","volume":"2019","author":"Y Asada","year":"2019","unstructured":"Asada Y, Takayanagi T, Kawakami T, Tomatsu E, Masuda A, Yoshino Y, Sekiguchi-Ueda S, Shibata M, Ide T, Niimi H (2019) Risedronate attenuates podocyte injury in phosphate transporter-overexpressing rats. Int J Endocrinol 2019(1):4194853","journal-title":"Int J Endocrinol"},{"key":"4870_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104432","author":"R Bhadange","year":"2025","unstructured":"Bhadange R, Gaikwad AB (2025) Unlocking new frontiers in kidney diseases: targeting endothelial dysfunction with emerging biomarkers and therapies. Drug Discov Today. https:\/\/doi.org\/10.1016\/j.drudis.2025.104432","journal-title":"Drug Discov Today"},{"key":"4870_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118124","volume":"187","author":"R Bhadange","year":"2025","unstructured":"Bhadange R, Dagar N, Gaikwad AB (2025) Levosimendan mitigates renal fibrosis via TGF-\u03b21\/Smad axis modulation in UUO rats. Biomed Pharmacother 187:118124","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"4870_CR6","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1007\/s00198-021-05944-0","volume":"32","author":"B Cardozo","year":"2021","unstructured":"Cardozo B, Karatza E, Karalis V (2021) Osteoporosis treatment with risedronate: a population pharmacokinetic model for the description of its absorption and low plasma levels. Osteoporos Int 32(11):2313\u20132321","journal-title":"Osteoporos Int"},{"key":"4870_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111140","volume":"125","author":"W Chen","year":"2023","unstructured":"Chen W, Zhao S, Xing J, Yu W, Rao T, Zhou X, Ruan Y, Li S, Xia Y, Song T (2023) BMAL1 inhibits renal fibrosis and renal interstitial inflammation by targeting the ERK1\/2\/ELK-1\/Egr-1 axis. Int Immunopharmacol 125:111140","journal-title":"Int Immunopharmacol"},{"key":"4870_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109953","author":"X Chen","year":"2024","unstructured":"Chen X, Shen R, Zhu D, Luo S, You G, Li R, Hong X, Li R, Wu J, Huang Y (2024) Drug repurposing opportunities for chronic kidney disease. iScience. https:\/\/doi.org\/10.1016\/j.isci.2024.109953","journal-title":"iScience"},{"key":"4870_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.8489","author":"N Dagar","year":"2025","unstructured":"Dagar N, Habshi T, Shelke V, Jadhav HR, Gaikwad AB (2025) Esculetin and phloretin combination mitigates acute kidney injury-diabetes comorbidity via regulating mitophagy and inflammation: a dual-pronged approach. Phytother Res. https:\/\/doi.org\/10.1002\/ptr.8489","journal-title":"Phytother Res"},{"issue":"5","key":"4870_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1208\/s12249-021-02078-8","volume":"22","author":"OA Elkady","year":"2021","unstructured":"Elkady OA, Saleh LM, Tadros MI, El-Laithy HM (2021) Nebulization of risedronate sodium microspheres for potential attenuation of pulmonary emphysema: a promising new insight of alveolar macrophage apoptosis. AAPS PharmSciTech 22(5):202","journal-title":"AAPS PharmSciTech"},{"issue":"7","key":"4870_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","volume":"20","author":"A Francis","year":"2024","unstructured":"Francis A, Harhay MN, Ong AC, Tummalapalli SL, Ortiz A, Fogo AB, Fliser D, Roy-Chaudhury P, Fontana M, Nangaku M (2024) Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol 20(7):473\u2013485","journal-title":"Nat Rev Nephrol"},{"key":"4870_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122095","author":"AB Gaikwad","year":"2023","unstructured":"Gaikwad AB (2023) Phloretin as an add-on therapy to losartan attenuates diabetes-induced AKI in rats: a potential therapeutic approach targeting TLR4-induced inflammation. Life Sci. https:\/\/doi.org\/10.1016\/j.lfs.2023.122095","journal-title":"Life Sci"},{"key":"4870_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/jpp\/rgaf002","author":"AB Gaikwad","year":"2025","unstructured":"Gaikwad AB (2025) Repurposing the familiar: future treatment options against chronic kidney disease. J Pharm Pharmacol. https:\/\/doi.org\/10.1093\/jpp\/rgaf002","journal-title":"J Pharm Pharmacol"},{"key":"4870_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.yjmcc.2019.11.146","volume":"138","author":"J Gao","year":"2020","unstructured":"Gao J, Shao K, Chen X, Li Z, Liu Z, Yu Z, Aung LHH, Wang Y, Li P (2020) The involvement of post-translational modifications in cardiovascular pathologies: focus on SUMOylation, neddylation, succinylation, and prenylation. J Mol Cell Cardiol 138:49\u201358","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"4870_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12325-021-02006-z","volume":"39","author":"JJ Garcia Sanchez","year":"2022","unstructured":"Garcia Sanchez JJ, Thompson J, Scott DA, Evans R, Rao N, S\u00f6rstadius E, James G, Nolan S, Wittbrodt ET, Abdul Sultan A (2022) Treatments for chronic kidney disease: a systematic literature review of randomized controlled trials. Adv Ther 39(1):193\u2013220","journal-title":"Adv Ther"},{"issue":"6","key":"4870_CR16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00774-023-01471-6","volume":"41","author":"S Harata","year":"2023","unstructured":"Harata S, Kasukawa Y, Nozaka K, Tsuchie H, Shoji R, Igarashi S, Kasama F, Oya K, Okamoto K, Miyakoshi N (2023) Effects of bisphosphonates and treadmill exercise on bone and kidney in adenine-induced chronic kidney disease rats. J Bone Miner Metab 41(6):785\u2013796","journal-title":"J Bone Miner Metab"},{"key":"4870_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119241","volume":"272","author":"NM Hassan","year":"2021","unstructured":"Hassan NM, Said E, Shehatou GS (2021) Nifuroxazide suppresses UUO-induced renal fibrosis in rats via inhibiting STAT-3\/NF-\u03baB signaling, oxidative stress and inflammation. Life Sci 272:119241","journal-title":"Life Sci"},{"issue":"1","key":"4870_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41392-023-01379-7","volume":"8","author":"R Huang","year":"2023","unstructured":"Huang R, Fu P, Ma L (2023) Kidney fibrosis: from mechanisms to therapeutic medicines. Signal Transduct Target Ther 8(1):129","journal-title":"Signal Transduct Target Ther"},{"key":"4870_CR19","doi-asserted-by":"publisher","first-page":"1365151","DOI":"10.3389\/fphar.2024.1365151","volume":"15","author":"AL Inselman","year":"2024","unstructured":"Inselman AL, Masters EA, Moore JN, Agarwal R, Gassman A, Kuijpers G, Beger RD, Delclos KB, Swift S, Camacho L (2024) The effect of black cohosh extract and risedronate coadministration on bone health in an ovariectomized rat model. Front Pharmacol 15:1365151","journal-title":"Front Pharmacol"},{"issue":"4","key":"4870_CR20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00774-020-01095-0","volume":"38","author":"H Ishida","year":"2020","unstructured":"Ishida H, Komaba H, Hamano N, Yamato H, Sawada K, Wada T, Nakamura M, Fukagawa M (2020) Skeletal and mineral metabolic effects of risedronate in a rat model of high-turnover renal osteodystrophy. J Bone Miner Metab 38(4):501\u2013510","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"4870_CR21","doi-asserted-by":"publisher","first-page":"4761925","DOI":"10.1155\/2018\/4761925","volume":"2018","author":"H Jin","year":"2018","unstructured":"Jin H, Wang Y, Wang D, Zhang L (2018) Effects of Qingshen granules on the oxidative stress-NF\/kB signal pathway in unilateral ureteral obstruction rats. Evid-Based Complement Alternat Med 2018(1):4761925","journal-title":"Evid-Based Complement Alternat Med"},{"key":"4870_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114915","volume":"164","author":"D Jung","year":"2023","unstructured":"Jung D, Bachmann HS (2023) Regulation of protein prenylation. Biomed Pharmacother 164:114915","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"4870_CR23","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.3390\/cells12121581","volume":"12","author":"SP Kadatane","year":"2023","unstructured":"Kadatane SP, Satariano M, Massey M, Mongan K, Raina R (2023) The role of inflammation in CKD. Cells 12(12):1581","journal-title":"Cells"},{"key":"4870_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-024-04331-y","author":"Y Khater","year":"2025","unstructured":"Khater Y, Barakat N, Shokeir A, Hamed M, Samy A, Karrouf G (2025a) Synergy of zinc oxide nanoparticles to losartan attenuates kidney injury induced by unilateral ureteral obstruction through modulation of the TNF-\u03b1\/IL6 and BAX\/BCL2 signaling pathways. Int Urol Nephrol. https:\/\/doi.org\/10.1007\/s11255-024-04331-y","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"4870_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00345-025-05580-x","volume":"43","author":"Y Khater","year":"2025","unstructured":"Khater Y, Barakat N, Shokeir A, Samy A, Karrouf G (2025b) Renal fibrosis progression following partial unilateral ureteral obstruction: mechanisms and therapeutic insights. World J Urol 43(1):1\u20136","journal-title":"World J Urol"},{"issue":"5","key":"4870_CR26","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/j.1472-8206.2012.01047.x","volume":"27","author":"NF Khedr","year":"2013","unstructured":"Khedr NF, El-Ashmawy NE, El-Bahrawy HA, Haggag AA, El-Abd EE (2013) Modulation of bone turnover in orchidectomized rats treated with raloxifene and risedronate. Fundam Clin Pharmacol 27(5):526\u2013534","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"4870_CR27","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3892\/br.2015.520","volume":"3","author":"B-B Kim","year":"2015","unstructured":"Kim B-B, Ko Y, Park J-B (2015) Effects of risedronate on the morphology and viability of gingiva-derived mesenchymal stem cells. Biomed Rep 3(6):845\u2013848","journal-title":"Biomed Rep"},{"key":"4870_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpet.2025.103609","author":"H Kulkarni","year":"2025","unstructured":"Kulkarni H, Dagar N, Gaikwad AB (2025) Uncovering the pharmacological mechanisms of bifendate against chronic kidney disease using computational pharmacology and experimental verification. J Pharmacol Exp Ther. https:\/\/doi.org\/10.1016\/j.jpet.2025.103609","journal-title":"J Pharmacol Exp Ther"},{"key":"4870_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176676","volume":"977","author":"H-L Kuo","year":"2024","unstructured":"Kuo H-L, Chuang H-L, Chen C-M, Chen Y-Y, Chen Y-S, Lin S-C, Weng P-Y, Liu T-C, Wang P-Y, Huang C-F (2024) Wogonin ameliorates ER stress-associated inflammatory response, apoptotic death and renal fibrosis in a unilateral ureteral obstruction mouse model. Eur J Pharmacol 977:176676","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"4870_CR30","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.bcp.2009.08.033","volume":"79","author":"L Li","year":"2010","unstructured":"Li L, Chen G-P, Yang Y, Ye Y, Yao L, Hu S-J (2010) Chronic inhibition of farnesyl pyrophosphate synthase attenuates cardiac hypertrophy and fibrosis in spontaneously hypertensive rats. Biochem Pharmacol 79(3):399\u2013406","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"4870_CR31","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/0886022X.2019.1612430","volume":"41","author":"W Li","year":"2019","unstructured":"Li W, Lu Y, Lou Y, Zhao S, Cui W, Wang Y, Luo M, Sun J, Miao L (2019) FFNT25 ameliorates unilateral ureteral obstruction-induced renal fibrosis. Ren Fail 41(1):419\u2013426","journal-title":"Ren Fail"},{"issue":"10","key":"4870_CR32","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.34067\/KID.0000000000000227","volume":"4","author":"J Liang","year":"2023","unstructured":"Liang J, Liu Y (2023) Animal models of kidney disease: challenges and perspectives. Kidney360 4(10):1479\u20131493","journal-title":"Kidney360"},{"issue":"2","key":"4870_CR33","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.bbrc.2018.01.066","volume":"496","author":"L Lin","year":"2018","unstructured":"Lin L, Li M, Lin L, Xu X, Jiang G, Wu L (2018) FPPS mediates TGF-\u03b21-induced non-small cell lung cancer cell invasion and the EMT process via the RhoA\/Rock1 pathway. Biochem Biophys Res Commun 496(2):536\u2013541","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"4870_CR34","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/15384101.2022.2139126","volume":"22","author":"X Liu","year":"2023","unstructured":"Liu X, Liu Y, Tang L, Du C (2023) Inhibition of farnesyl pyrophosphate synthase alleviates cardiomyopathy in diabetic rat. Cell Cycle 22(6):666\u2013679","journal-title":"Cell Cycle"},{"key":"4870_CR35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.archoralbio.2016.03.021","volume":"68","author":"M Malavasi","year":"2016","unstructured":"Malavasi M, Louro R, Barros MB, Teixeira LN, Peruzzo DC, Joly JC, Martinez EF, Napimoga MH (2016) Effects of risedronate on osteoblastic cell cultures. Arch Oral Biol 68:43\u201347","journal-title":"Arch Oral Biol"},{"issue":"4","key":"4870_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3390\/biom9040141","volume":"9","author":"E Mart\u00ednez-Klimova","year":"2019","unstructured":"Mart\u00ednez-Klimova E, Aparicio-Trejo OE, Tapia E, Pedraza-Chaverri J (2019) Unilateral ureteral obstruction as a model to investigate fibrosis-attenuating treatments. Biomolecules 9(4):141","journal-title":"Biomolecules"},{"issue":"1","key":"4870_CR37","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.bone.2013.08.018","volume":"57","author":"JB Matheny","year":"2013","unstructured":"Matheny JB, Slyfield CR, Tkachenko EV, Lin I, Ehlert KM, Tomlinson RE, Wilson DL, Hernandez CJ (2013) Anti-resorptive agents reduce the size of resorption cavities: a three-dimensional dynamic bone histomorphometry study. Bone 57(1):277\u2013283","journal-title":"Bone"},{"key":"4870_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115407","volume":"137","author":"MR McClung","year":"2020","unstructured":"McClung MR, Ebetino FH (2020) History of risedronate. Bone 137:115407","journal-title":"Bone"},{"issue":"2","key":"4870_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae004","volume":"8","author":"CE Metzger","year":"2024","unstructured":"Metzger CE, Kittaka M, LaPlant AN, Ueki Y, Allen MR (2024) Inhibition of RANKL improves the skeletal phenotype of adenine-induced chronic kidney disease in mice. JBMR plus 8(2):ziae004","journal-title":"JBMR plus"},{"issue":"1","key":"4870_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-68303-z","volume":"14","author":"RH Mohamed","year":"2024","unstructured":"Mohamed RH, Abdelrahim DS, Hay NHA, Fawzy NM, M DKM, Yehia DAY, AbdelMaksoud OM, Tamim YM (2024) The role of protein prenylation inhibition through targeting FPPS by zoledronic acid in the prevention of renal fibrosis in rats. Sci Rep 14(1):18283","journal-title":"Sci Rep"},{"issue":"6","key":"4870_CR41","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.7150\/thno.100969","volume":"15","author":"Z Niu","year":"2025","unstructured":"Niu Z, Guo J, Liu X, Chen M, Jin Y, Yao M, Li X, Che Q, Li S, Zhang C (2025) Renal tubular epithelial-derived follistatin-like 1 protects against UUO-induced renal fibrosis in mice via inhibiting NF-\u03baB-mediated epithelial inflammation. Theranostics 15(6):2413","journal-title":"Theranostics"},{"issue":"8","key":"4870_CR42","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41581-024-00837-x","volume":"20","author":"H Noels","year":"2024","unstructured":"Noels H, Jankowski V, Schunk SJ, Vanholder R, Kalim S, Jankowski J (2024) Post-translational modifications in kidney diseases and associated cardiovascular risk. Nat Rev Nephrol 20(8):495\u2013512","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"4870_CR43","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1152\/physrev.00027.2022","volume":"103","author":"R N\u00f8rregaard","year":"2023","unstructured":"N\u00f8rregaard R, Mutsaers HA, Fr\u00f8ki\u00e6r J, Kwon T-H (2023) Obstructive nephropathy and molecular pathophysiology of renal interstitial fibrosis. Physiol Rev 103(4):2847\u20132892","journal-title":"Physiol Rev"},{"issue":"1","key":"4870_CR44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.kint.2017.12.026","volume":"94","author":"U Panchapakesan","year":"2018","unstructured":"Panchapakesan U, Pollock C (2018) Drug repurposing in kidney disease. Kidney Int 94(1):40\u201348","journal-title":"Kidney Int"},{"key":"4870_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2025.107044","volume":"207","author":"B Puri","year":"2025","unstructured":"Puri B, Majumder S, Gaikwad AB (2025) CRISPR\/Cas9 based knockout of lncRNA MALAT1 attenuates TGF-\u03b21 induced Smad 2\/3 mediated fibrosis during AKI-to-CKD transition. Eur J Pharm Sci 207:107044","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"4870_CR46","doi-asserted-by":"publisher","first-page":"14892","DOI":"10.1096\/fj.202000737RRR","volume":"34","author":"H Ren","year":"2020","unstructured":"Ren H, Zuo S, Hou Y, Shang W, Liu N, Yin Z (2020) Inhibition of \u03b11-adrenoceptor reduces TGF-\u03b21-induced epithelial-to-mesenchymal transition and attenuates UUO-induced renal fibrosis in mice. FASEB J 34(11):14892\u201314904","journal-title":"FASEB J"},{"key":"4870_CR47","doi-asserted-by":"publisher","first-page":"1335094","DOI":"10.3389\/fphar.2023.1335094","volume":"14","author":"N Ren","year":"2024","unstructured":"Ren N, Wang W-F, Zou L, Zhao Y-L, Miao H, Zhao Y-Y (2024) The nuclear factor kappa B signaling pathway is a master regulator of renal fibrosis. Front Pharmacol 14:1335094","journal-title":"Front Pharmacol"},{"key":"4870_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.70036","author":"YK Talati","year":"2025","unstructured":"Talati YK, Dagar N, Gaikwad AB (2025) Flavokawain a attenuated chronic kidney disease: evidence from network pharmacology and experimental verification. Cell Biol Int. https:\/\/doi.org\/10.1002\/cbin.70036","journal-title":"Cell Biol Int"},{"key":"4870_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.899469","volume":"13","author":"L Tanner","year":"2022","unstructured":"Tanner L, Bergwik J, Single AB, Bhongir RK, Erjef\u00e4lt JS, Egesten A (2022) Zoledronic acid targeting of the mevalonate pathway causes reduced cell recruitment and attenuates pulmonary fibrosis. Front Pharmacol 13:899469","journal-title":"Front Pharmacol"},{"key":"4870_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2021.106073","volume":"139","author":"CY Ung","year":"2021","unstructured":"Ung CY, Onoufriadis A, Parsons M, McGrath JA, Shaw TJ (2021) Metabolic perturbations in fibrosis disease. Int J Biochem Cell Biol 139:106073","journal-title":"Int J Biochem Cell Biol"},{"issue":"4","key":"4870_CR51","doi-asserted-by":"publisher","first-page":"R163","DOI":"10.1186\/ar3122","volume":"12","author":"MT Valenti","year":"2010","unstructured":"Valenti MT, Giannini S, Donatelli L, Zanatta M, Bertoldo F, Sella S, Vilei MT, Ossi E, Realdi G, Lo Cascio V (2010) The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation. Arthritis Res Ther 12(4):R163","journal-title":"Arthritis Res Ther"},{"key":"4870_CR52","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S321879","author":"J Wang","year":"2021","unstructured":"Wang J, Ge S, Wang Y, Liu Y, Qiu L, Li J, Huang X, Sun L (2021) Puerarin alleviates UUO-induced inflammation and fibrosis by regulating the NF-\u03baB P65\/STAT3 and TGF\u03b21\/Smads signaling pathways. Drug des Devel Ther. https:\/\/doi.org\/10.2147\/DDDT.S321879","journal-title":"Drug des Devel Ther"},{"key":"4870_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.607968","volume":"11","author":"Y-H Wei","year":"2021","unstructured":"Wei Y-H, Liao S-L, Wang S-H, Wang C-C, Yang C-H (2021) Simvastatin and ROCK inhibitor Y-27632 inhibit myofibroblast differentiation of Graves\u2019 ophthalmopathy-derived orbital fibroblasts via RhoA-mediated ERK and p38 signaling pathways. Front Endocrinol 11:607968","journal-title":"Front Endocrinol"},{"issue":"1","key":"4870_CR54","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41392-023-01439-y","volume":"8","author":"X Wu","year":"2023","unstructured":"Wu X, Xu M, Geng M, Chen S, Little PJ, Xu S, Weng J (2023) Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies. Signal Transduct Target Ther 8(1):220","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"4870_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186012","volume":"12","author":"T Ye","year":"2017","unstructured":"Ye T, Cao P, Qi J, Zhou Q, Rao DS, Qiu S (2017) Protective effect of low-dose risedronate against osteocyte apoptosis and bone loss in ovariectomized rats. PLoS ONE 12(10):e0186012","journal-title":"PLoS ONE"},{"issue":"6","key":"4870_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.70024","volume":"27","author":"D Ye","year":"2025","unstructured":"Ye D, Zhang C, Shao W, Lin L, Chen X, Wu L (2025) FPPS downregulation attenuates endoplasmic reticulum stress in pulmonary epithelial cells. J Gene Med 27(6):e70024","journal-title":"J Gene Med"},{"issue":"1","key":"4870_CR57","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13765-024-00858-x","volume":"67","author":"Z Yu","year":"2024","unstructured":"Yu Z, He W, Shi W (2024) Sulforaphane (Sul) reduces renal interstitial fibrosis (RIF) by controlling the inflammation and TGF-\u03b2\/Smad signaling pathway. Appl Biol Chem 67(1):8","journal-title":"Appl Biol Chem"},{"issue":"1","key":"4870_CR58","doi-asserted-by":"publisher","first-page":"2085303","DOI":"10.1155\/2020\/2085303","volume":"2020","author":"D Zhao","year":"2020","unstructured":"Zhao D, Luan Z (2020) Oleanolic acid attenuates renal fibrosis through tgf-\u03b2\/smad pathway in a rat model of unilateral ureteral obstruction. Evid-Based Complement Alternat Med 2020(1):2085303","journal-title":"Evid-Based Complement Alternat Med"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04870-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04870-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04870-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:16:12Z","timestamp":1776316572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04870-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4870"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04870-w","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"20 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments in the study were conducted in accordance with the ARRIVE guidelines and approved by the Institutional Animal Ethics Committee (IAEC\/RES\/34\/04).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics, consent to participate, and consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}